A

The headline shows how a $1,000 investment in Agilent Technologies a decade ago would have grown. It highlights the potential long‑term gains of holding popular stocks.

Agilent Technologies (NYSE:A) executives outlined continued growth momentum, driven by improving end markets, market-share gains, instrument replacement cycles and operational changes under the company’s Ignite transformation program, during a J.P. Morgan conference discussion. Chief Executive Offi

The article reports that Agilent Technologies presented a transcript at the U.S. All Stars Conference.

The piece reviews Agilent’s performance in the Q2 research tools and consumables earnings season, comparing it to peers.

The headline notes that Agilent, along with Thermo Fisher and Moderna, has overbought RSI readings above 70, suggesting possible short‑term weakness.

Demand is rising for real-time biomolecular analysis in drug discovery and diagnostics, driven by SPR/BLI advances, automation, high-throughput screening and biomarker research.Dublin, Sept.

AI-enabled, microfluidic label-free detection is expanding in drug discovery, early diagnostics, food safety and environmental testing, driven by efficient, non-invasive, sustainable workflows.Dublin, Sept.

China lithium prices slide as key mine loses licence, while major producers’ profits and Argentina expansion plans reshape 2027 supply outlook. See more here.